PGEN Debt / Equity | PRECIGEN, INC.

PRECIGEN, INC. (PGEN) Debt / Equity

2022-12-31: Debt/Equity Ratio 0.34.
2022-09-30: Debt/Equity Ratio 0.58.
2022-06-30: Debt/Equity Ratio 3.57.
2022-03-31: Debt/Equity Ratio 2.73.

Complete source-backed debt/equity ratio history.

Available history: 2013-09-30 to 2022-12-31
Data captured: 2026-09-04

Historical Debt/Equity Ratio

Date	Debt/Equity Ratio
2022-12-31	0.34
2022-09-30	0.58
2022-06-30	3.57
2022-03-31	2.73
2021-12-31	1.68
2021-09-30	1.37
2021-06-30	1.11
2021-03-31	1
2020-12-31	2.56
2020-09-30	3.32
2020-06-30	4.51
2020-03-31	2.53
2019-12-31	3.04
2019-09-30	0.94
2019-06-30	0.76
2019-03-31	0.69
2018-12-31	0.58
2018-09-30	0.34
2018-06-30	0.01
2018-03-31	0.01
2017-12-31	0.02
2017-09-30	0.02
2017-06-30	0.01
2017-03-31	0.02
2016-12-31	0.01
2016-09-30	0.01
2016-06-30	0.01
2016-03-31	0.01
2015-12-31	0.01
2015-09-30	0.01
2015-06-30	0.02
2015-03-31	0.02
2014-12-31	0.03
2014-09-30	0.03
2013-12-31	0
2013-09-30	0.01

Annual Debt/Equity Ratio

Date	Debt/Equity Ratio
2022-12-31	0.34
2021-12-31	1.68
2020-12-31	2.56
2019-12-31	3.04
2018-12-31	0.58
2017-12-31	0.02
2016-12-31	0.01
2015-12-31	0.01
2014-12-31	0.03
2013-12-31	0

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
NewAmsterdam Pharma Co N.V. (NAMS)		$2.719B	-15.37
MBX Biosciences, Inc. (MBX)	United States	$2.664B	-25.36
Disc Medicine, Inc. (IRON)	United States	$2.553B	-11.40
Immunome Inc. (IMNM)	United States	$2.538B	-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)	United States	$2.517B	-24.63
Nurix Therapeutics, Inc. (NRIX)	United States	$2.457B	-5.39
Dyne Therapeutics, Inc. (DYN)	United States	$3.084B	-7.09
SELLAS Life Sciences Group, Inc. (SLS)	United States	$2.420B	-91.87
uniQure N.V. (QURE)		$2.416B	-4.93
Vera Therapeutics, Inc. (VERA)	United States	$2.402B	-7.67